MINOR MODIFICATIONS TO NIH-APPROVED HUMAN GENE TRANSFER PROTOCOLS 
( 380 ) 

Z.^ 
O '■ 
■■■:.. ■ 
S ' 
g 
a ' 
O . 
.. 2 . 
oi/'- 
' I " 
- 'y^ 
❖ 
5„' A ; 
U ^/''' / . V- 
' y, '' 
' 
'y , , , - 
Lift the cap on the number of patients accrued onto the protocol. 
Use the retrovirus vector, GlNa, instead of LNL6. 
Use the retrovirus vector, GlNa, instead of LNL6. 
Use the retrovirus vector, GlNa, instead of LNL6. 
Extend patient eligibility criteria to include patients with advanced breast cancer. 
fl) Eliminate systemic IL-4 therapy, and (2) allow administration of cyclophosphamide prior to TIL infusions. 
Increase patient accrual from 3 to 5 patients. 
(1) addition of assays for anti-DNA antibodies on day 28 and week 8; (2) repeat chest and abdominal CTs, when indicated, at 
6-8 weeks following initial treatment; (3) additional biopsies performed on days 16 and 20 and as needed to verify gene 
expression; (4) reduce the duration of the protocol from 16 to 8 weeks; and (5) expand patient eligibility to include those 
patients who have tolerated previous treatments without side effects at higher doses. 
Deliver HLA-B7 DNA liposome complexes by catheter to pulmonary nodules. 
Use only irradiated SK-RC-39 cell line, not SK-RC-28. 
New transduction protocol which allows the use of autologous stroma and growth factors. 
Revised transduction procedure that includes the use of autologous stroma and growth factors. 
Treat 2 ADA-deficient newborns (1 at Children's Hospital Los Angeles and 1 at the National Institutes of Health) with ADA 
gene-corrected autologous hematopoietic stem cells obtained from the patients' umbilical cord and placenta. 
1 
Decrease the T>ascline* and 'Sehicle control’ portions of the protocol from 1 month to 1 week each. 
i 
Rosenberg, Steven K. 
Brenner, Malcolm K., et. 
al. 
u 
u 
E 
1 
m 
2 
b 
c 
e 
E . 
o « 
Brenner, Malcolm K., ec. 
al. 
Rosenberg, Steven K. 
Lotze, Michael T. 
Wilson, James M. 
Nabel, Gary J. 
Nabel, Gary J. 
Gansbacber, Bemd, et al. 
Deisseroth, Albert R 
Deisseroth, Albert B. 
Blaese, R. Michael 
Crystal, Ronald G. 
t 
S 
9102-004 
oJ 
9102-006 
010-0116 
9105-009 
a 
§ 
ON 
9202-013 
I 
1 
9105-007 
9206-020 
1 
3/2/89 
7/12/91 
7/U/91 
1 
10/15/91 
1A7/92 
11/14/91 
1 
1 
< 
8/14/92 
7/12/91 
1 
00 
9/6/90 
Major 
Amendment 
4/22/92 
1 
DATE OF 
MINOR 
MODIFI- 
CATION 
3/30/90 
11/91 
§ 
11/91 
in/72 
11/30/92 
U/3/92 
1/93 
g 
3/31/93 
9s 
1 
4/21/93 
Recombinant DNA Research, Volume 19 
